User profiles for HESHAM MOHAMED
Hesham A. Mohamed, Ph.D IEEE Senior MemberAssociate Professor, Electronics Research Institute Verified email at eri.sci.eg Cited by 662 |
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)
…, MB Bradley-Garelik, H Mohamed… - Blood, The Journal …, 2014 - ashpublications.org
This analysis explores the impact of early cytogenetic and molecular responses on the
outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase 3 …
outcomes of patients with chronic myeloid leukemia in chronic phase (CML-CP) in the phase 3 …
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
…, A Hochhaus, P Rousselot, H Mohamed… - Blood, The Journal …, 2014 - ashpublications.org
We present long-term follow-up of a dasatinib phase 3 study of patients with imatinib-resistant/-intolerant
chronic myeloid leukemia (CML). In the CA180-034 study, 670 patients with …
chronic myeloid leukemia (CML). In the CA180-034 study, 670 patients with …
Dasatinib in imatinib‐resistant or‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034
…, JE Cortes, J Milone, H Mohamed… - American journal of …, 2016 - Wiley Online Library
Dasatinib was approved at 100 mg once daily for imatinib‐resistant or ‐intolerant patients with
chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180…
chronic myeloid leukemia (CML) in chronic phase, based on results of the phase 3 CA180…
Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
…, J Brevard, P Henrick, H Mohamed… - The Lancet …, 2023 - thelancet.com
Background Olutasidenib (FT-2102) is a potent, selective, oral, small-molecule inhibitor of
mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase 1/2 study were …
mutant isocitrate dehydrogenase 1 (IDH1). The aims for phase 1 of this phase 1/2 study were …
Printed millimeter-wave MIMO-based slot antenna arrays for 5G networks
AAR Saad, HA Mohamed - AEU-International Journal of Electronics and …, 2019 - Elsevier
In this work, a broadband millimeter-wave (mm-wave) multiple-input–multiple-output (MIMO)
antenna system for upcoming fifth generation (5G) networks is presented. The MIMO …
antenna system for upcoming fifth generation (5G) networks is presented. The MIMO …
Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial
…, A Sedkov, J Brevard, PF Kelly, H Mohamed… - Neuro …, 2023 - academic.oup.com
Background Olutasidenib (FT-2102) is a highly potent, orally bioavailable, brain-penetrant
and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim of the study was …
and selective inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). The aim of the study was …
[HTML][HTML] Flexible and frequency reconfigurable CPW-fed monopole antenna with frequency selective surface for IoT applications
AA Ibrahim, HA Mohamed, MA Abdelghany… - scientific reports, 2023 - nature.com
This paper proposes a flexible, frequency-reconfigurable monopole antenna design with
frequency selective surface (FSS) for Internet of Things (IoT) applications. The proposed …
frequency selective surface (FSS) for Internet of Things (IoT) applications. The proposed …
Single‐fed 4G/5G multiband 2.4/5.5/28 GHz antenna
In this study, a single‐fed printed multiband antenna for 4G/5G wireless communication
systems is presented. The proposed multiband antenna consists of Franklin strip monopole …
systems is presented. The proposed multiband antenna consists of Franklin strip monopole …
Design and implementation of UWB slot-loaded printed antenna for microwave and millimeter wave applications
…, W Swelam, A Allam, MFA Sree, HA Mohamed - IEEE …, 2021 - ieeexplore.ieee.org
In this paper, single-layer ultra-Wide Band (UWB) microstrip patch antennas loaded with
asymmetrical U-shaped slot in both microwave and millimeter wave applications are presented. …
asymmetrical U-shaped slot in both microwave and millimeter wave applications are presented. …
Odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): results from a prespecified analysis of the pivotal phase II study ELM …
…, J Li, M Ufkin, M Zhu, A Chaudhry, H Mohamed… - Blood, 2022 - ashpublications.org
Background Odronextamab is a hinge-stabilized, human IgG4-based CD20× CD3 bispecific
antibody (Ab) that binds CD20 on B cells and CD3 on T cells, triggering T-cell-mediated …
antibody (Ab) that binds CD20 on B cells and CD3 on T cells, triggering T-cell-mediated …